{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:57:58Z","timestamp":1780459078982,"version":"3.54.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p><jats:italic>Candida auris<\/jats:italic> is an emerging yeast which, since its first isolation about a decade ago, has spread rapidly and triggered major infectious outbreaks in health care facilities around the world. <jats:italic>C. auris<\/jats:italic> strains often display resistance to clinically-used antifungal agents, contributing to high mortality rates. Thus, there is an urgent need for new antifungals to contain the spread of this emerging multi-drug resistant pathogen and to improve patient outcomes. However, the timeline for the development of a new antifungal agent typically exceeds 10\u201115 years. Thus, repurposing of current drugs could significantly accelerate the development and eventual deployment of novel therapies for the treatment of <jats:italic>C. auris<\/jats:italic> infections. Toward this end, in this study we have profiled a library of known drugs encompassing approximately 12,000 clinical-stage or FDA-approved small molecules in search for known molecules with antifungal activity against <jats:italic>C. auris<\/jats:italic>; more specifically, those capable of inhibiting <jats:italic>C. auris<\/jats:italic> biofilm formation. From this library, 100 compounds displaying antifungal activity were identified in the initial screen, including 26 compounds for which a dose-response relationship with biofilm-inhibitory activity against <jats:italic>C. auris<\/jats:italic> could be confirmed. Of these, five were identified as the most interesting potential repositionable candidates. Due to their known pharmacological and human safety profiles, identification of such compounds should allow for their accelerated preclinical and clinical development for the treatment of <jats:italic>C. auris<\/jats:italic> infections.<\/jats:p>","DOI":"10.3389\/fcimb.2020.597931","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T06:35:59Z","timestamp":1606286159000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Screening the CALIBR ReFRAME Library in Search for Inhibitors of Candida auris Biofilm Formation"],"prefix":"10.3389","volume":"10","author":[{"given":"Gina","family":"Wall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell V.","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"Lopez-Ribot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discovery"},{"key":"B2","unstructured":"BiopharmaceuticalsE.\n          About Lonafarnib [Online]. Eiger Biopharmaceuticals2018"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1017\/ice.2017.162","article-title":"Effectiveness of Disinfectants Against Candida auris and Other Candida Species","volume":"38","author":"Cadnum","year":"2017","journal-title":"Infect. Control. Hosp. Epidemiol."},{"key":"B4","unstructured":"Recommendations for treatment of Candida auris [Online]. Centers for Disease Control and Prevention2018"},{"key":"B5","unstructured":"Candida auris [Online]. Centers for Disease Control and Prevention2019"},{"key":"B6","unstructured":"Tracking Candida auris [Online]. Centers for Disease Control and Prevention2019"},{"key":"B7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jhin.2016.08.004","article-title":"Multidrug-resistant Candida auris: \u2018new kid on the block\u2019 in hospital-associated infections","volume":"94","author":"Chowdhary","year":"2016","journal-title":"J. Hosp. Infect."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006290","article-title":"Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally","volume":"13","author":"Chowdhary","year":"2017","journal-title":"PloS Pathog."},{"key":"B9","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/jac\/dkx480","article-title":"A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolate-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance","volume":"73","author":"Chowdhary","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00083","article-title":"Identification of Off-Patent Compounds That Present Antifungal Activity Against the Emerging Fungal Pathogen Candida auris","volume":"9","author":"de Oliveira","year":"2019","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/jof5030084","article-title":"Hospital Laboratory Survey for Identification of Candida auris in Belgium","volume":"5","author":"Dewaele","year":"2019","journal-title":"J. Fungi (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1367-5931(99)80063-5","article-title":"Muscarinic receptor ligands and their therapeutic potential","volume":"3","author":"Eglen","year":"1999","journal-title":"Curr. Opin. Chem. Biol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"11559","DOI":"10.1038\/s41598-018-29973-8","article-title":"A phenotypic small-molecule screen identifies halogenated salicylanilides as inhibitors of fungal morphogenesis, biofilm formation and host cell invasion","volume":"8","author":"Garcia","year":"2018","journal-title":"Sci. Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ja.2008.3","article-title":"Micafungin: a sulfated echinocandin","volume":"62","author":"Hashimoto","year":"2009","journal-title":"J. Antibiot. (Tokyo)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/jof5030058","article-title":"On the Origins of a Species: What Might Explain the Rise of Candida auris","volume":"5","author":"Jackson","year":"2019","journal-title":"J. Fungi (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"10750","DOI":"10.1073\/pnas.1810137115","article-title":"The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis","volume":"115","author":"Janes","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jhin.2017.11.015","article-title":"Surface disinfection challenges for Candida auris: an in-vitro study","volume":"98","author":"Kean","year":"2018","journal-title":"J. Hosp. Infect."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/jof6010030","article-title":"Candida auris: A Decade of Understanding of an Enigmatic Pathogenic Yeast","volume":"6","author":"Kean","year":"2020","journal-title":"J. Fungi (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.00726","article-title":"Candida auris: Disinfectants and Implications for Infection Control","volume":"9","author":"Ku","year":"2018","journal-title":"Front. Microbiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02396-16","article-title":"The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation","volume":"61","author":"Larkin","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B22","unstructured":"Provecta: A new approach to the inhibition of resistance to insecticides252253\n            LiszkaD.\n            DhangP.\n          Int. Pest Control.562014"},{"key":"B23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/cid\/ciw691","article-title":"Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses","volume":"64","author":"Lockhart","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.2174\/09298673113206660262","article-title":"Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis","volume":"20","author":"Moorthy","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/534314a","article-title":"Can you teach old drugs new tricks","volume":"534","author":"Nosengo","year":"2016","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.15585\/mmwr.mm6901a2","article-title":"Candida auris Isolates Resistant to Three Classes of Antifungal Medications - New Yor","volume":"69","author":"Ostrowsky","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1017\/ice.2017.127","article-title":"Environmental Surfaces in Healthcare Facilities are a Potential Source for Transmission of Candida auris and Other Candida Species","volume":"38","author":"Piedrahita","year":"2017","journal-title":"Infect. Control Hosp Epidemiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/nport.2008.141","article-title":"A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing","volume":"3","author":"Pierce","year":"2008","journal-title":"Nat. Protoc."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1099\/jmm.0.001036","article-title":"Candida auris: a comparison between planktonic and biofilm susceptibility to antifungal drugs","volume":"68","author":"Romera","year":"2019","journal-title":"J. Med. Microbiol."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.03081","article-title":"Candida auris: What Have We Learned About Its Mechanisms of Pathogenicity","volume":"9","author":"Rossato","year":"2018","journal-title":"Front. Microbiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3201\/eid2302.161320","article-title":"Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant Candida auris","volume":"23","author":"Sherry","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s11095-006-0254-1","article-title":"Dealing with Time-Dependent Pharmacokinetics during the Early Clinical Development of a New Leukotriene B4 Synthesis Inhibitor","volume":"23","author":"Troc\u00f3niz","year":"2006","journal-title":"Pharm. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1089\/photob.2018.4604","article-title":"Biomedical Applications of Photo- and Sono-Activated Rose Bengal: A Review","volume":"37","author":"Vanerio","year":"2019","journal-title":"Photobiomodul Photomed Laser Surg."},{"key":"B34","doi-asserted-by":"publisher","first-page":"7611","DOI":"10.1128\/AAC.01890-15","article-title":"In Vitro Activity of Miltefosine against Candida albicans under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral Candidiasis","volume":"59","author":"Vila","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3390\/antibiotics9080445","article-title":"Current Antimycotics, New Prospects, and Future Approaches to Antifungal Therapy","volume":"9","author":"Wall","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00924-20","article-title":"Screening Repurposing Libraries for the Identification of Drugs with Novel Antifungal Activity","volume":"64","author":"Wall","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01084-18","article-title":"Screening a Repurposing Library for Inhibitors of Multidrug-Resistant Candida auris Identifies Ebselen as a Repositionable Candidate for Antifungal Drug Development","volume":"62","author":"Wall","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B38","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/jof5040092","article-title":"Repositionable Compounds with Antifungal Activity against Multidrug Resistant Candida auris Identified in the Medicines for Malaria Venture\u2019s Pathogen Box","volume":"5","author":"Wall","year":"2019","journal-title":"J. Fungi (Basel)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1128\/JCM.00921-17","article-title":"Survival, Persistence, and Isolation of the Emerging Multidrug-Resistant Pathogenic Yeast Candida auris on a Plastic Health Care Surface","volume":"55","author":"Welsh","year":"2017","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1517\/13543784.2012.688950","article-title":"Lonafarnib for cancer and progeria","volume":"21","author":"Wong","year":"2012","journal-title":"Expert Opin. Invest. Drugs"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2020.597931\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T06:36:13Z","timestamp":1606286173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2020.597931\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,25]]},"references-count":40,"alternative-id":["10.3389\/fcimb.2020.597931"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2020.597931","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,25]]},"article-number":"597931"}}